Apogee Therapeutics Inc [APGE] stock is trading at $36.14, up 1.98%. An important factor to consider is whether the stock is rising or falling in short-term value. The APGE shares have gain 14.95% over the last week, with a monthly amount drifted -12.56%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on November 25, 2024, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $89. Previously, BofA Securities started tracking the stock with Buy rating on May 10, 2024, and set its price target to $80. On December 20, 2023, BTIG Research initiated with a Buy rating and assigned a price target of $43 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $40 on August 08, 2023. TD Cowen initiated its recommendation with a Outperform. Stifel started tracking with a Buy rating for this stock on August 08, 2023, and assigned it a price target of $34. In a note dated August 08, 2023, Jefferies initiated an Buy rating and provided a target price of $29 on this stock.
Apogee Therapeutics Inc [APGE] stock has fluctuated between $29.10 and $72.29 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $36.14 at the most recent close of the market. An investor can expect a potential return of 162.87% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.22 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.08 points at the first support level, and at 34.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.25, and for the 2nd resistance point, it is at 38.36.
Ratios To Look Out For
For context, Apogee Therapeutics Inc’s Current Ratio is 18.55. On the other hand, the Quick Ratio is 18.55, and the Cash Ratio is 4.96.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Mar 05 ’25 when 1590.0 shares were sold. Chief Executive Officer, HENDERSON MICHAEL THOMAS completed a deal on Mar 05 ’25 to sell 10000.0 shares. Meanwhile, Officer HENDERSON MICHAEL THOMAS bought 10000.0 shares on Mar 05 ’25.
